IP Library › Granted Patent US 12,285,503
Granted Patent B2
US 12,285,503 · App. 18/363,369 · Granted Apr 29, 2025

Methods and reagents for tumor targeting with greater efficacy and less toxicity

Inventor: Neil H. Bander (Chappaqua, NY)
Assignee: CORNELL UNIVERSITY
A61K51/1072A61K51/0402A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,503
App. No.
18/363,369
Granted
Apr 29, 2025
Kind
B2
Abstract

The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and/or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.

Claims (19)

1. A method for treating prostate cancer in a subject, the method comprising co-administering to a subject in need thereof, a therapeutically effective amount of J591-Ac 225 and a therapeutically effective amount of a PSMA ligand/inhibitor wherein the PSMA ligand/inhibitor is a PSMA-Lu 177 peptide.

2. The method of claim 1 , wherein the PSMA-Lu 177 peptide is PSMA I&T-Lu 177 or PSMA 617-Lu 177 .

3. The method of claim 1 , wherein the J591-Ac 225 and PSMA-L 177 peptide are administered in separate compositions.

4. The method of claim 3 , wherein the separate compositions are administered to the subject by injection.

5. The method of claim 3 , wherein the separate compositions are co-administered via simultaneous administration, sequential administration, continuous administration, or a combination thereof to the subject.

6. The method of claim 5 , wherein the separate compositions are administered in a 2 week cycle.

7. The method of claim 1 , wherein J591-Ac 225 and PSMA ligand/inhibitor are co-administered to the subject to allow for J591-Ac 225 and PSMA ligand/inhibitor to be dosed at about 25% to about 100% of their respective maximum tolerated doses.

8. The method of claim 7 , wherein the PSMA ligand/inhibitor is a PSMA-Lu 177 peptide.

9. The method of claim 8 , wherein the PSMA-Lu 177 peptide is PSMA I&T-Lu 177 or PSMA 617-Lu 177 .

10. A combination therapeutic comprising: a therapeutically effective amount of J591-Ac 225 and a therapeutically effective amount of a PSMA ligand/inhibitor wherein the PSMA ligand/inhibitor is a PSMA-Lu 177 peptide.

11. The combination therapeutic of claim 10 , wherein the PSMA-Lu 177 peptide is PSMA 617-Lu 177 or PSMA I&T-Lu 177 .

12. The combination therapeutic of claim 10 , wherein the J591-Ac 225 and the PSMA ligand/inhibitor are in the same or in separate compositions.

13. The combination therapeutic of claim 12 , wherein the J591-Ac 225 and the PSMA ligand/inhibitor are in separate compositions.

14. The combination therapeutic of claim 13 , wherein the separate compositions are formulated for injection to a subject.

15. The combination therapeutic of claim 13 , wherein the separate compositions are formulated for co-administration via simultaneous administration, sequential administration, continuous administration, or a combination thereof to a subject.

16. The combination therapeutic of claim 13 , wherein the separate compositions are administered to a subject in a 2 week cycle.

17. The combination therapeutic of claim 10 , wherein the combination therapeutic is formulated for administration to a subject to deliver the J591-Ac 225 and PSMA ligand/inhibitor peptide at a dose of about 25% to about 100% of their respective maximum tolerated doses.

18. The combination therapeutic of claim 17 , wherein the PSMA ligand/inhibitor is a PSMA-Lu 177 peptide.

19. The combination therapeutic of claim 18 , wherein the PSMA-Lu 177 peptide is PSMA 617-Lu 177 or PSMA I&T-Lu 177 .

Continuity (4)
Continuation 17198574 · Mar 11, 2021
Continuation 16610816
Provisional Application 62500187 · May 2, 2017
Related Publication 20240000980A1 · Jan 4, 2024
References Cited (115)
US 6683162B2 · Scheinberg et al. · 2004 [cited by applicant]
US 7011812B1 · Griffiths et al. · 2006 [cited by applicant]
US 7514078B2 · Bander · 2009 [cited by examiner]
US 7666414B2 · Bander · 2010 [cited by applicant]
US 8778305B2 · Pomper et al. · 2014 [cited by applicant]
US 8889631B2 · Peterson · 2014 [cited by applicant]
US 8926944B2 · Babich et al. · 2015 [cited by applicant]
US 9223981B2 · Itani · 2015 [cited by applicant]
US 9289519B2 · Scheinberg et al. · 2016 [cited by applicant]
US 9364554B2 · Hutchinson et al. · 2016 [cited by applicant]
US 9388144B2 · Babich et al. · 2016 [cited by applicant]
US 9574006B2 · Lazar et al. · 2017 [cited by applicant]
US 9694091B2 · Pomper et al. · 2017 [cited by applicant]
US 9776977B2 · Pomper et al. · 2017 [cited by applicant]
US 9789195B2 · Cheng et al. · 2017 [cited by applicant]
US 10179117B2 · Babich et al. · 2019 [cited by applicant]
US 10603276B2 · Fahmy et al. · 2020 [cited by applicant]
US 10980901B2 · Morgenstern et al. · 2021 [cited by applicant]
US 11059903B2 · Holgate et al. · 2021 [cited by applicant]
US 11491247B2 · Bander · 2022 [cited by applicant]
US 11738101B2 · Bander · 2023 [cited by applicant]
US 20030138432A1 · Glazier · 2003 [cited by applicant]
US 20060088539A1 · Bander · 2006 [cited by applicant]
US 20120322672A1 · Hua et al. · 2012 [cited by applicant]
US 20150110814A1 · Olson et al. · 2015 [cited by applicant]
US 20150148294A1 · Marks et al. · 2015 [cited by applicant]
US 20150190529A1 · Peterson et al. · 2015 [cited by applicant]
US 20150232560A1 · Heindl et al. · 2015 [cited by applicant]
US 20160228587A1 · Eder et al. · 2016 [cited by applicant]
US 20160256579A1 · Shalom · 2016 [cited by applicant]
US 20170002076A1 · Kim et al. · 2017 [cited by applicant]
US 20170014528A1 · Sengupta et al. · 2017 [cited by applicant]
US 20170037142A1 · Bander · 2017 [cited by applicant]
US 20170081298A1 · Ray et al. · 2017 [cited by applicant]
US 20170189568A1 · Kung et al. · 2017 [cited by applicant]
US 20170246327A1 · Kopka et al. · 2017 [cited by applicant]
US 20180051039A1 · Pomper et al. · 2018 [cited by applicant]
US 20180085478A1 · Pomper et al. · 2018 [cited by applicant]
US 20180104353A1 · Sengupta et al. · 2018 [cited by applicant]
US 20180148514A1 · Williams · 2018 [cited by applicant]
US 20200281955A1 · Xu et al. · 2020 [cited by applicant]
US 20200339625A1 · Lin et al. · 2020 [cited by applicant]
US 20210154338A1 · Bander · 2021 [cited by applicant]
US 20210196844A1 · Bander · 2021 [cited by applicant]
US 20220081401A1 · Narayanan et al. · 2022 [cited by applicant]
US 20230364271A1 · Bander · 2023 [cited by applicant]
US 20240000979A1 · Bander · 2024 [cited by applicant]
WO 0053236A2 · 2000 [cited by applicant]
WO 02098897A2 · 2002 [cited by applicant]
WO 2003024388A2 · 2003 [cited by applicant]
WO 2005070456A2 · 2005 [cited by applicant]
WO 2011108955A1 · 2011 [cited by applicant]
WO 2013009475A1 · 2013 [cited by applicant]
WO 2015057250A1 · 2015 [cited by applicant]
WO 2016123591A2 · 2016 [cited by applicant]
WO 2017165473A1 · 2017 [cited by applicant]
WO 2018204477A1 · 2018 [cited by applicant]
WO 2020126064A1 · 2020 [cited by applicant]
WO 2022072293A2 · 2022 [cited by applicant]
Kristell L.S. Chatlic et al. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent, Theranostics, 6(6), 849-861. (Year: 2016). [cited by examiner]
Office Action in U.S. Appl. No. 17/198,574 (mailed Oct. 20, 2021). [cited by applicant]
Office Action in U.S. Appl. No. 17/198,574 (mailed Jun. 10, 2021). [cited by applicant]
Office Action in U.S. Appl. No. 17/198,574 (mailed Jul. 11, 2022). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/024363 (mailed Jul. 2, 2024). [cited by applicant]
Kratochwil et al., “Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding,” J. Nuclear Medicine 58:1624-1631 (2017). [cited by applicant]
Sharkey R. M. et al., “Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models,” Molecular Cancer Therapeutics, 10(6)… [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US18/30620, mailed Jul. 13, 2018. [cited by applicant]
Papademetriou I. T. et al., “In Vivo Performance of Polymer Nanocarriers Dually-Targeted to Epitopes of the Same or Different Receptors,” Biomaterials, 34(13): 3459-3466 (2013). [cited by applicant]
Extended European Search Report and Opinion for European Application No. 18794018.4 (dated Dec. 21, 2020). [cited by applicant]
Niaz et al., “PD16-11 Comparison of Prostate-Specific Membrane Antigen (PSMA)—Targeted Radionuclide Therapy (TRT) with Lutetium-177 LU)-L-177) via Antibody, J591 vs. Small Molecule Ligand PSMA-617”, The Journal of Urolo… [cited by applicant]
Gerber et al., “Combining Antibody-Drug Conjugates and Immune-Mediated Cancer Therapy: What to Expect?,” Biochemical Pharmacology 102:1-6 (2015). [cited by applicant]
Mugra et al., “Synergistic Co-Targeting of Prostate-Specific Membrane Antigen and Androgen Receptor in Prostate Cancer,” The Prostate 75(3):242-254 (2014). [cited by applicant]
Kiess et al., “Prostate-Specific Membrane Antigen as a Target for Cancer Imaging and Therapy,” Q J Nucl Med Mol Imaging 59(3):241-268 (2015). [cited by applicant]
Bander et al., “Phase 1 Clinical Trial Targeting a monoclonal Antibody (MAB) to the Extracellular Domain of Prostate Specific Membrane Antigen (PSMAEXT) in Hormone-Independent Patients,” Journal of Urology 163(4):160 (2… [cited by applicant]
Bander et al., “Targeting Metastatic Prostate Cancer with Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen,” J. Urology 170:1717-1721 (2003). [cited by applicant]
Smith-Jones et al., “In Vitro Characterization of Radiolabeled Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-Specific Membrane Antigen,” Cancer Res. 60(18):5237-5243 (2000). [cited by applicant]
Bander et al., “Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer,” J. Clin. Oncol. 23(21):4591-4601 (2005). [cited by applicant]
Kudgus, et al., “Tuning Pharmacokinetics and Biodistribution of a Targeted Drug Delivery System Through Incorporation of a Passive Targeting Component,” Scientific Reports, 4:5669 (1-9) (2014). [cited by applicant]
Office Action in U.S. Appl. No. 16/610,816 (mailed Oct. 5, 2021). [cited by applicant]
Office Action in Japan Application No. 2019-560384 (issued Dec. 20, 2021). [cited by applicant]
Kratochwil et al., “PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617,” J. Nucl. Med. 57(8):1170-1176 (2016). [cited by applicant]
Restriction Requirement in U.S. Appl. No. 16/610,816 (mailed Apr. 29, 2021). [cited by applicant]
Kratochwil et al., “Targeted Alpha Therapy of mCRPC: Dosimetry Estimate of 213Bismuth-PSMA-617,” Eur. J. Nucl. Med. Mol. Imaging 45:31-37 (2018). [cited by applicant]
Sartor et al., “Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer,” N. Engl. J. Med. 385 (12):1091-1103 (2021) [Author Manuscript]. [cited by applicant]
Kabasakal et al., “Pre-Therapeutic Dosimetry of Normal Organs and Tissues of 177Lu-PSMA-617 Prostate-Specific Membrane Antigen (PSMA) Inhibitor in Patients with Castration-Resistant Prostate Cancer,” Eur. J. Nucl. Med. … [cited by applicant]
NCRP, “Misadministration of Radioactive Material in Medicine—Scientific Background,” NCRP Commentary No. 7, Chapter 4: p. 27 (1991). [cited by applicant]
Bodei et al., “Long-Term Evaluation of Renal Toxicity After Peptide Receptor Radionuclide Therapy with 90Y-Dotatoc and 177Lu-Dotatate: The Role of Associated Risk Factors,” Eur. J. Nucl. Med. Mol. Imaging 35:1847-1856 (… [cited by applicant]
Delker et al., “Dosimetry for 177Lu-DKFZ-PSMA-617: A New Radiopharmaceutical for the Treatment of Metastatic Prostate Cancer,” Eur. J. Nucl. Med. Mol. Imaging 43:42-51 (2016). [cited by applicant]
Emami et al., “Tolerance of Normal Tissue to Therapeutic Irradiation,” Int. J. Radiation Oncol. Biol. Phys. 21(1): 109-122 (1991). [cited by applicant]
Fendler, et al., “Preliminary Experience with Dosimetry, Response and Patient Reported Outcome After 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer,” Oncotarget 8(2):3581-3590 (2017). [cited by applicant]
Okamoto et al., “Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions,” J. Nucl. Med. 58(3):445-450 (2017). [cited by applicant]
Gleisner et al., “EANM Dosimetry Committee Recommendations for Dosimetry of 177Lu-labelled Somatostatin-Receptor- and PSMA-Targeting Ligands,” Eur. J. Nucl. Med. Mol. Imaging (2022), 49:1778-1809. [cited by applicant]
Deasy et al., “Radiotherapy Dose-vol. Effects on Salivary Gland Function,” Int. J. Radiat. Oncol. Biol. Phys. 76(3 Suppl):S58-63 (2010) [Author Manuscript]. [cited by applicant]
Paganelli et al., “Dosimetry and Safety of 177Lu PSMA-617 along with Polyglutamate Parotid Gland Protector: Preliminary Results in Metastatic Castration-Resistant Prostate Cancer Patients,” Eur. J. Nucl. Med. Mol. Imagi… [cited by applicant]
Afshar-Oromieh et al., “The Diagnostic Value of PET/CT Imaging with the 68Ga-Labelled PSMA Ligand HBED-CC in the Diagnosis of Recurrent Prostate Cancer,” Eur. J. Nucl. Med. Mol. Imaging 42:197-209 (2015). [cited by applicant]
Afshar-Oromieh et al., “Repeated PSMA-Targeting Radioligand Therapy of Metastatic Prostate Cancer with 131I-MIP-1095,” Eur. J. Nucl. Med. Mol. Imaging 44:950-959 (2017). [cited by applicant]
Van Kalmthout et al., “Impact of External Cooling with Icepacks on 68Ga-PSMA Uptake in Salivary Glands,” EJNMMI Res. 8:56 (2018). [cited by applicant]
Yilmaz et al., “Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands,” J. Nucl. Med. 60:1388-1393 (2019). [cited by applicant]
National Cancer Institute, “Radiation Therapy to Treat Cancer”, accessed at www.cancer.gov/about-cancer/treatment/types/radiation-therapy. [cited by applicant]
Gale, R.P., “Combination Cancer Therapy,” Merck Manual Consumer Version accessed at: https://www.merckmanuals.com/home/cancer/prevention-and-treatment-of-cancer/combination-cancer-therapy. [cited by applicant]
Al-Lazikani et al., “Combinatorial Drug Therapy for Cancer in the Post-Genomic Era,” Nat. Biotechnol. 30(7):679-692 (2012). [cited by applicant]
“How is Chemotherapy Used to Treat Cancer,” American Cancer Society accessed at: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/how-is-chemotherapy-used-to-treat-cancer.html. [cited by applicant]
ClinicalTrials.gov Identifier NCT04886986 accessed at: https://clinicaltrials.gov/ct2/show/NCT04886986. [cited by applicant]
Sarnelli et al., “Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol,” Molecules 24:621 (2019). [cited by applicant]
Vallabhajosula et al., “Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu?… [cited by applicant]
Pandit-Taskar et al., “89Zr-huJ591 Immuno-PET Imaging in Patients with Advanced Metastatic Prostate Cancer,” Eur. J. Nucl. Med. Mol. Imaging 41(11):2093-2105 (2014) [Author Manuscript]. [cited by applicant]
Haberkorn et al., “New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy,” Clin. Cancer Res. 22(1):9-15 (2016). [cited by applicant]
Lütje et al., “PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status,” Theranostics 5 (12):1388-1401 (2015). [cited by applicant]
Tagawa et al., “Anti-Prostate-Specific Membrane Antigen-Based Radioimmunotherapy for Prostate Cancer,” Cancer 116(4 Suppl):1075-1083 (2010). [cited by applicant]
Zechman et al., “Radiation Dosimetry and First Therapy Results with a 1241/ 1311-Labeled Small Molecule (MIP-1095) Targeting PSMA for Prostate Cancer Therapy,” Eur. J. Nucl. Med. Mol. Imaging 41:1280-1292 (2014). [cited by applicant]
Notice of Reasons for Rejection in Japan Patent Application No. 2019-560384 (mailed Sep. 1, 2022). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US21/52269 (mailed Feb. 3, 2022). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US21/52271 (mailed May 12, 2022). [cited by applicant]
Third Notice of Reasons for Rejection in Japanese Patent Application No. 2019-560384, mailed Apr. 26, 2023. [cited by applicant]
Kristell L.S. Chatalic et al., “Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent,” Theranostics 6(6):849-861 (2016). [cited by applicant]